348 related articles for article (PubMed ID: 37833558)
1. MYC in liver cancer: mechanisms and targeted therapy opportunities.
Liu F; Liao Z; Zhang Z
Oncogene; 2023 Nov; 42(45):3303-3318. PubMed ID: 37833558
[TBL] [Abstract][Full Text] [Related]
2. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500
[TBL] [Abstract][Full Text] [Related]
3. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
Amicone L; Terradillos O; Calvo L; Costabile B; Cicchini C; Della Rocca C; Lozupone F; Piacentini M; Buendia MA; Tripodi M
Oncogene; 2002 Feb; 21(9):1335-45. PubMed ID: 11857077
[TBL] [Abstract][Full Text] [Related]
4. MYC activation is a hallmark of cancer initiation and maintenance.
Gabay M; Li Y; Felsher DW
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
Sipos F; Firneisz G; Műzes G
World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
[TBL] [Abstract][Full Text] [Related]
6. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.
Vízkeleti L; Spisák S
Cells; 2023 Jun; 12(13):. PubMed ID: 37443779
[TBL] [Abstract][Full Text] [Related]
7. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
8. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
9. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
10. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo.
Stein TJ; Bowden M; Sandgren EP
Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of "undruggable" MYC.
Llombart V; Mansour MR
EBioMedicine; 2022 Jan; 75():103756. PubMed ID: 34942444
[TBL] [Abstract][Full Text] [Related]
13. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
14. Impact of MYC in regulation of tumor cell metabolism.
Wahlström T; Henriksson MA
Biochim Biophys Acta; 2015 May; 1849(5):563-9. PubMed ID: 25038584
[TBL] [Abstract][Full Text] [Related]
15. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
Aravalli RN; Talbot NC; Steer CJ
World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
[TBL] [Abstract][Full Text] [Related]
17. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.
Dang H; Takai A; Forgues M; Pomyen Y; Mou H; Xue W; Ray D; Ha KCH; Morris QD; Hughes TR; Wang XW
Cancer Cell; 2017 Jul; 32(1):101-114.e8. PubMed ID: 28697339
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between oncogenic MYC and noncoding RNAs in cancer.
Tu R; Chen Z; Bao Q; Liu H; Qing G
Semin Cancer Biol; 2021 Oct; 75():62-71. PubMed ID: 33160022
[TBL] [Abstract][Full Text] [Related]
20. MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis.
Meškytė EM; Keskas S; Ciribilli Y
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]